CU20180028A7 - DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN - Google Patents

DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Info

Publication number
CU20180028A7
CU20180028A7 CUP2018000028A CU20180028A CU20180028A7 CU 20180028 A7 CU20180028 A7 CU 20180028A7 CU P2018000028 A CUP2018000028 A CU P2018000028A CU 20180028 A CU20180028 A CU 20180028A CU 20180028 A7 CU20180028 A7 CU 20180028A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
dyrk1
piridine
clk1
useful
Prior art date
Application number
CUP2018000028A
Other languages
English (en)
Spanish (es)
Inventor
Balázs Bálint
Michaël Frank Burbridge
Francisco Humberto Cruzalegui
Nicolas Foloppe
András Kotschy
Melinda Sipos
David Walmsley
Csaba Wéber
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CU20180028A7 publication Critical patent/CU20180028A7/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CUP2018000028A 2015-09-30 2016-09-30 DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN CU20180028A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559252A FR3041639B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
PCT/EP2016/073395 WO2017055530A1 (fr) 2015-09-30 2016-09-30 Nouveaux dérivés d'imidazo[4,5-b]pyridine utilisés comme inhibiteurs de dyrk1/clk1 doubles

Publications (1)

Publication Number Publication Date
CU20180028A7 true CU20180028A7 (es) 2018-07-05

Family

ID=54979755

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2018000028A CU20180028A7 (es) 2015-09-30 2016-09-30 DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN

Country Status (26)

Country Link
US (1) US20180273528A1 (fr)
EP (1) EP3356363A1 (fr)
JP (1) JP2018535931A (fr)
KR (1) KR20180054858A (fr)
CN (1) CN108137581A (fr)
AU (1) AU2016333505A1 (fr)
BR (1) BR112018006157A2 (fr)
CA (1) CA2999935A1 (fr)
CL (1) CL2018000783A1 (fr)
CO (1) CO2018003473A2 (fr)
CR (1) CR20180181A (fr)
CU (1) CU20180028A7 (fr)
DO (1) DOP2018000083A (fr)
EA (1) EA201890821A1 (fr)
EC (1) ECSP18023253A (fr)
FR (1) FR3041639B1 (fr)
HK (1) HK1255804A1 (fr)
IL (1) IL258341A (fr)
MA (1) MA43020A (fr)
MX (1) MX2018003860A (fr)
NI (1) NI201800043A (fr)
PE (1) PE20181331A1 (fr)
PH (1) PH12018500650A1 (fr)
SV (1) SV2018005657A (fr)
TN (1) TN2018000090A1 (fr)
WO (1) WO2017055530A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
CN108822103A (zh) * 2018-07-28 2018-11-16 刘凤娟 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2021050824A1 (fr) * 2019-09-11 2021-03-18 Prelude Therapeutics Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques
WO2026024933A1 (fr) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970200A1 (fr) * 2013-03-13 2016-01-20 Abbvie Inc. Inhibiteurs de pyridine cdk9 kinase

Also Published As

Publication number Publication date
KR20180054858A (ko) 2018-05-24
TN2018000090A1 (en) 2019-07-08
EP3356363A1 (fr) 2018-08-08
CO2018003473A2 (es) 2018-07-10
MA43020A (fr) 2018-08-08
CA2999935A1 (fr) 2017-04-06
FR3041639B1 (fr) 2019-01-25
EA201890821A1 (ru) 2018-10-31
NI201800043A (es) 2018-06-21
PH12018500650A1 (en) 2018-10-01
JP2018535931A (ja) 2018-12-06
FR3041639A1 (fr) 2017-03-31
CL2018000783A1 (es) 2018-09-21
SV2018005657A (es) 2018-07-31
BR112018006157A2 (pt) 2018-10-09
CN108137581A (zh) 2018-06-08
HK1255804A1 (zh) 2019-08-23
WO2017055530A1 (fr) 2017-04-06
ECSP18023253A (es) 2018-04-30
MX2018003860A (es) 2018-08-16
CR20180181A (es) 2018-06-22
DOP2018000083A (es) 2018-10-15
AU2016333505A1 (en) 2018-04-19
US20180273528A1 (en) 2018-09-27
IL258341A (en) 2018-05-31
PE20181331A1 (es) 2018-08-20

Similar Documents

Publication Publication Date Title
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
ECSP18053634A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005656A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
CU20170160A7 (es) Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen
UY35467A (es) Compuestos orgánicos
CR20150045A (es) Inhibidores de hepatitis c
CR20140275A (es) Triazolopiridinas sustituidas
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen